<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760771</url>
  </required_header>
  <id_info>
    <org_study_id>EASE-IT-TF</org_study_id>
    <nct_id>NCT02760771</nct_id>
  </id_info>
  <brief_title>Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)</brief_title>
  <acronym>EASE-IT-TF</acronym>
  <official_title>Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty&#xD;
      (BAV) is often performed under rapid right ventricular pacing (burst &gt;180 bpm) with the&#xD;
      induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation aims&#xD;
      at facilitating the crossing of the aortic annulus, accurate valve positioning and does also&#xD;
      provide information on the anatomy of the valve complex. However, BAV has been shown to have&#xD;
      a number of potentially detrimental effects.&#xD;
&#xD;
      There is limited experience for the balloon expandable Edwards THV on the need for&#xD;
      predilation (BAV). Experience so far has only been documented from smaller, uncontrolled case&#xD;
      series.&#xD;
&#xD;
      The investigators aim to document the incidence of several kinds of complications in a large,&#xD;
      multicenter registry / prospective controlled cohort study to identify associations between&#xD;
      patient related variables and outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic valve predilation aims at facilitating the crossing of the aortic annulus, accurate&#xD;
      valve positioning and does also provide information on the anatomy of the valve complex.&#xD;
      However, BAV has been shown to have a number of potentially detrimental effects, such as:&#xD;
&#xD;
        -  Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral,&#xD;
           and renal ischemia.&#xD;
&#xD;
        -  In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac&#xD;
           depression after rapid pacing is observed and may result in hemodynamic failure and&#xD;
           systemic inflammatory response syndrome (SIRS). Both are associated with a high&#xD;
           periprocedural mortality.&#xD;
&#xD;
        -  BAV has been identified as a major source of thrombotic and valvular material, thus&#xD;
           increasing the risk for coronary obstruction with subsequent myocardial infarction&#xD;
           and/or stroke.&#xD;
&#xD;
        -  The local trauma in the left-ventricular outflow tract caused by BAV may potentially&#xD;
           contribute to aortic root rupture.&#xD;
&#xD;
      The investigators aim to document the incidence of cerebrovascular complications,&#xD;
      paravalvular leakage and operative outcomes in a large, multicenter registry / prospective&#xD;
      controlled cohort study to identify associations between patient related variables and&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Combination of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pacemaker implantation</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>within 30 days after TAVI</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">196</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>with BAV</arm_group_label>
    <description>patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without BAV</arm_group_label>
    <description>patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>with BAV</intervention_name>
    <description>balloon dilation of the aortic valve prior to implantation of the THV</description>
    <arm_group_label>with BAV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>without BAV</intervention_name>
    <description>no balloon dilation of the aortic valve prior to implantation of the THV</description>
    <arm_group_label>without BAV</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for transfemoral transcatheter valve implantation with commercially&#xD;
        available Edwards Transcatheter Heart Valves.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Males or females&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Logistic EuroSCORE I &gt;40%&#xD;
&#xD;
          -  Mitral or tricuspid valvular insufficiency (&gt; grade II)&#xD;
&#xD;
          -  Previous aortic valve replacement&#xD;
&#xD;
          -  Uncontrolled atrial fibrillation&#xD;
&#xD;
          -  Left ventricular or atrial thrombus by echocardiography&#xD;
&#xD;
          -  High probability of non-adherence to the follow-up requirements (due to social,&#xD;
             psychological or medical reasons)&#xD;
&#xD;
          -  Patients with mobile structures on the leaflets&#xD;
&#xD;
          -  Need for a cerebral protection device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Schymick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtisches Klinikum Karlsruhe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wendt, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westdeutsches Herzzentrum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik IV, Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://ippmed-easeittf.s4trials-europe.net</url>
    <description>registry on-line eCRF website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>THV (trans-catheter heart valve)</keyword>
  <keyword>severe aortic stenosis</keyword>
  <keyword>pre-dilation</keyword>
  <keyword>rapid pacing</keyword>
  <keyword>BAV (balloon artery valvuloplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

